| |
Unadjusted
|
Adjusteda
|
|---|
|
Baseline variables
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
Gender (male vs. female)
|
1.73 (1.15–2.61)
|
0.009
|
1.60 (1.00–2.57)
|
0.053
|
|
WHO stage (IV vs. I–III)
|
2.71 (1.64–4.49)
|
<0.001
|
1.46 (0.81–2.65)
|
0.210
|
|
ART start year (vs. 2003–04)
| | | | |
|
2005
|
0.55 (0.35–0.87)
|
0.010
|
0.64 (0.38–1.08)
|
0.091
|
|
2006
|
0.30 (0.17–0.56)
|
<0.001
|
0.40 (0.19–0.83)
|
0.014
|
|
BMI (vs. ≥ 18.5 kg/m2)
| | | | |
|
<16
|
4.17 (2.29–7.60)
|
<0.001
|
2.12 (1.06–4.24)
|
0.034
|
|
16–18.4
|
1.60 (0.82–3.10)
|
0.168
|
1.27 (0.62–2.61)
|
0.516
|
|
Hemoglobin (vs. ≥ 12 g/dL for women and ≥ 13 for men)
| | | | |
|
<8
|
22.7 (5.40–95.7)
|
<0.001
|
9.20 (2.05–41.3)
|
0.004
|
|
8–9.9
|
13.5 (3.28–55.9)
|
<0.001
|
7.50 (1.77–31.9)
|
0.006
|
|
10–11.9 (10–12.9 for men)
|
6.21 (1.46–26.5)
|
0.014
|
4.03 (0.93–17.5)
|
0.063
|
|
TLC (vs. ≥ 1.2 × 109/L)
| | | | |
|
<0.6
|
3.58 (2.05–6.24)
|
<0.001
|
1.72 (0.87–3.39)
|
0.117
|
|
0.6–1.1
|
1.10 (0.69–1.74)
|
0.699
|
0.79 (0.48–1.32)
|
0.371
|
|
Platelet count (<150 vs. ≥ 150 × 109/L)
|
2.23 (1.40–3.57)
|
0.001
|
2.30 (1.33–3.99)
|
0.003
|
-
aCox proportional hazards model adjusted for all variables listed in the table.
- HR, hazard ratio; CI, confidence interval; ART, antiretroviral therapy; WHO, World Health Organization; BMI, body mass index; TLC, total lymphocyte count.
